Fresenius Medical Care AG & Co. KGaA (“the company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today announced the pricing of two tranches of euro- and U.S. dollar-denominated senior unsecured notes (together the “senior notes”). Proceeds amounting to approximately $950 million from the offering will be used for acquisitions, to refinance indebtedness and for general corporate purposes.

The coupon for the euro-denominated senior notes in the principal amount of €400 million due 2018 will be 6.5% and the coupon for the dollar-denominated senior notes in the principal amount of $400 million due 2018 will also be 6.5%.

Michael Brosnan, chief financial officer of the company, commented: “We are very pleased to have successfully completed this offering at favorable rates in the current market environment. It demonstrates our financial stability and flexibility for further pursuing our strategy of sustainable growth.“

The euro-denominated senior notes were offered by FMC Finance VIII S.A., and the dollar-denominated senior notes were offered by Fresenius Medical Care US Finance II, Inc. Both issuers are wholly-owned subsidiaries of the company. The senior notes were offered through a private placement to institutional investors and will be guaranteed jointly and severally by the company and its subsidiaries, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.

The senior notes have not been registered under the Securities Act of 1933 as amended, but were offered to “qualified institutional buyers” (QIBs) in the U.S. pursuant to the exemption from registration provided by Rule 144A under the Securities Act and in exempted “offshore transactions” pursuant to Regulation S under the Securities Act. The senior notes may not be offered or sold in the U.S. unless registered under the Securities Act or pursuant to an applicable exemption from registration requirements.

Application has been made for admission of the senior notes to trading on the regulated market of the Luxembourg Stock Exchange.